fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Clindamycin

All products: not a benefit

Dalacin T 1% · DIN 00582301 · 1% · Top Sol

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-17 — choose a marketed DIN from the same-category list.Discontinued December 17, 2021 · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-12-17 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Dalacin T 1% · DIN 00582301 Manufacturer: Pfizer Canada Inc.; listing date 2017-03-28 Health Canada: Cancelled post market since 2021-12-17 · brand DALACIN T 1% · ATC D10AF01 CLINDAMYCIN · form Solution · route Topical · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1 %/W/V · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Dalacin T 1%: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00582301)

Source record
DIN 00582301: Dalacin T 1% Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840404017; group id 809; item number 1987; lccId None; manufacturer id PFI Source form: Top Sol; strength: 1% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00582301 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11260
Interchangeable products
Taro-Clindamycin · DIN 02266938 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since December 17, 2021 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D10AF): coverage varies; not interchangeable

  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Adapalene + benzoyl peroxide + clindamycin (Cabtreo): limited Use 724
Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE Some products covered without a code (check the product listing): MUPIROCIN 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: acne
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE · Limited Use, codes 724 1 INDICATIONS CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00076715.PDF; date AUG 14, 2024; DIN 02550423; fetched 2026-09-10 Product monograph TAZAROTENE · Limited Use, codes 636 1 INDICATIONS ARAZLO™ (tazarotene lotion), is indicated for: • For the topical treatment of acne vulgaris in patients 10 years of age and older. 1.1 Pediatrics Pediatrics (≥ 10 years of age) The safety and efficacy of ARAZLO in pediatric patients (10 years of age and older) has been established. PM: https://pdf.hres.ca/dpd_pm/00082613.PDF; date NOV 28, 2025; DIN 02517868; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Taro-Clindamycin 1% (clindamycin phosphate) is indicated for the treatment of acne vulgaris. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALACIN T and other antibacterial drugs, DALACIN T should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Geriatrics (> 65 years of age): Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. Pediatrics Safety and effectiveness in pediatric patients under the age of 12 have not been established. https://pdf.hres.ca/dpd_pm/00058691.PDF PM date: not printed or not captured Source product: TARO-CLINDAMYCIN; DIN 02266938; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Dalacin T 1%: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026